A detailed history of Kynam Capital Management, LP transactions in Celldex Therapeutics, Inc. stock. As of the latest transaction made, Kynam Capital Management, LP holds 2,900,000 shares of CLDX stock, worth $96.6 Million. This represents 12.77% of its overall portfolio holdings.

Number of Shares
2,900,000
Previous 3,005,904 3.52%
Holding current value
$96.6 Million
Previous $119 Million 2.1%
% of portfolio
12.77%
Previous 13.34%

Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

SELL
$35.22 - $51.88 $3.73 Million - $5.49 Million
-105,904 Reduced 3.52%
2,900,000 $122 Million
Q4 2023

Feb 14, 2024

SELL
$22.61 - $40.65 $4.39 Million - $7.89 Million
-194,096 Reduced 6.07%
3,005,904 $119 Million
Q3 2023

Nov 14, 2023

BUY
$25.45 - $37.46 $15.3 Million - $22.5 Million
600,000 Added 23.08%
3,200,000 $88.1 Million
Q2 2023

Aug 14, 2023

BUY
$30.29 - $38.28 $36.1 Million - $45.6 Million
1,190,549 Added 84.47%
2,600,000 $88.2 Million
Q1 2023

May 15, 2023

SELL
$34.78 - $47.43 $6.81 Million - $9.29 Million
-195,939 Reduced 12.21%
1,409,451 $50.7 Million
Q4 2022

Feb 14, 2023

BUY
$27.78 - $45.38 $146,206 - $238,834
5,263 Added 0.33%
1,605,390 $71.6 Million
Q3 2022

Nov 14, 2022

BUY
$22.7 - $37.57 $10.6 Million - $17.6 Million
467,868 Added 41.32%
1,600,127 $45 Million
Q2 2022

Aug 15, 2022

BUY
$20.5 - $37.33 $7.77 Million - $14.2 Million
379,225 Added 50.36%
1,132,259 $30.5 Million
Q1 2022

May 13, 2022

BUY
$27.64 - $39.32 $14.5 Million - $20.7 Million
526,308 Added 232.13%
753,034 $25.6 Million
Q4 2021

Feb 14, 2022

BUY
$35.68 - $56.27 $8.09 Million - $12.8 Million
226,726 New
226,726 $8.76 Million

Others Institutions Holding CLDX

About Celldex Therapeutics, Inc.


  • Ticker CLDX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,772,400
  • Market Cap $1.56B
  • Description
  • Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-01...
More about CLDX
Track This Portfolio

Track Kynam Capital Management, LP Portfolio

Follow Kynam Capital Management, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Kynam Capital Management, LP, based on Form 13F filings with the SEC.

News

Stay updated on Kynam Capital Management, LP with notifications on news.